Benin

Population 2018: 11 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>6.5 (4.2–9.3)</td>
<td>96 (37–81)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.94 (0.61–1.4)</td>
<td>8.2 (5.3–12)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>0.1 (0.02–0.25)</td>
<td>0.89 (0.18–2.2)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>1 (0.6–1.5)</td>
<td>8.8 (5.2–13)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.32 (0.2–0.46)</td>
<td>2.8 (1.8–4)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- % tested with rapid diagnostics at time of diagnosis
- % with known HIV status 98%
- % pulmonary 92%
- % bacteriologically confirmed** 89%
- % children aged 0-14 years 5%
- % women 32%
- % men 63%

Total cases notified 4 066

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018 62% (43–95)
TB patients facing catastrophic total costs
TB case fatality ratio (estimated mortality/estimated incidence), 2018 21% (11–33)

HIV-negative TB mortality 1 (0.6–1.5) 8.8 (5.2–13)
HIV-positive TB mortality 0.32 (0.2–0.46) 2.8 (1.8–4)

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance**
- New cases 31%
- Previously treated cases 100%

Laboratory-confirmed cases* MDR/RR-TB: 27, XDR-TB: 0
Patients started on treatment* ** MDR/RR-TB: 24, XDR-TB: 0

MDR/RR-TB cases tested for resistance to second-line drugs 25

Treatment success rate and cohort size

New and relapse cases registered in 2017 87% 3 561
Previously treated cases, excluding relapse, registered in 2017 80% 96
HIV-positive TB cases registered in 2017 77% 549
MDR/RR-TB cases started on second-line treatment in 2016 82% 11
XDR-TB cases started on second-line treatment in 2016 0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment 7%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 86% (79–94)

TB financing, 2019

National TB budget (US$ millions) 3.6
Funding source: 7% domestic, 59% international, 34% unfunded

*Ranges represent uncertainty intervals
**MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
***Calculated for pulmonary cases only
*Includes cases with unknown previous TB treatment history
**Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-01-11 Data: www.who.int/tb/data